Lirametostat

DB14581InvestigationalSmall molecule

Potent and selective histone methyltransferase EZH2 inhibitor.

Mechanism: Pharmacologically active on Histone-lysine N-methyltransferase EZH2
Curator reviewed
Formula / weight: C₂₇H₃₃F₃N₄O₃ · 518.581 g/mol (avg)
Code names: CPI-1205

Resolves to

Compound

Structure

InChIKeyHPODOLXTMDHLLC-QGZVFWFLSA-NSMILESCOC1=C(CNC(=O)C2=C(C)N([C@H](C)C3CCN(CC(F)(F)F)CC3)C3=CC=CC=C23)C(=O)NC(C)=C1

Targets

What you can answer from here — as of October 27, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lirametostat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.